文献速递泌尿男性生殖肿瘤

帕博利珠单抗联合奥拉帕利治疗经治且未筛选生物标志物的转移性去势抵抗性前列腺癌:随机开放标签III期KEYLYNK-010试验

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
PubMed 文献 · J Clin Oncol · 2023-06-08

KEYLYNK-010研究比较帕博利珠单抗联合奥拉帕利与新一代激素药物(NHA)在未筛选生物标志物、经治转移性去势抵抗性前列腺癌(mCRPC)患者中的疗效。结果显示联合组与NHA组的中位影像学无进展生存期(rPFS)分别为4.4个月和4.2个月(HR 1.02,P=0.55),中位总生存期(OS)分别为15.8个月和14.6个月(HR 0.94,P=0.26),均无显著改善。研究因无效而终止。

要点

  • 帕博利珠单抗联合奥拉帕利较NHA未显著改善rPFS(HR 1.02)或OS(HR 0.94)。
  • 联合组客观缓解率(ORR)为16.8%,NHA组为5.9%。
  • 联合组≥3级治疗相关不良事件发生率为34.6%,NHA组为9.0%。

核心结论

  • 在未筛选生物标志物、经治的mCRPC患者中,帕博利珠单抗联合奥拉帕利较NHA未显著改善rPFS或OS,研究因无效而终止,未出现新的安全性信号。

研究设计与样本

  • III期、开放标签、随机(2:1)KEYLYNK-010研究,纳入经阿比特龙或恩扎卢胺(非两者)及多西他赛治疗后进展的mCRPC患者。
  • 2019年5月30日至2021年7月16日,共529例随机分配至帕博利珠单抗联合奥拉帕利组,264例至NHA组(阿比特龙或恩扎卢胺)。
  • 双主要终点为盲法独立中心审查按PCWG改良RECIST 1.1评估的rPFS和OS。

主要发现

  • 最终rPFS分析:联合组中位rPFS为4.4个月(95%CI 4.2-6.0),NHA组为4.2个月(95%CI 4.0-6.1),HR 1.02(95%CI 0.82-1.25),P=0.55。
  • 最终OS分析:联合组中位OS为15.8个月(95%CI 14.6-17.0),NHA组为14.6个月(95%CI 12.6-17.3),HR 0.94(95%CI 0.77-1.14),P=0.26。
  • 最终TFST分析:联合组中位TFST为7.2个月(95%CI 6.7-8.1),NHA组为5.7个月(95%CI 5.0-7.1),HR 0.86(95%CI 0.71-1.03)。
  • ORR:联合组为16.8%,NHA组为5.9%。
  • ≥3级治疗相关不良事件发生率:联合组为34.6%,NHA组为9.0%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is an unmet need for therapeutic options that prolong survival for patients with heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC). The phase III, open-label KEYLYNK-010 study evaluated pembrolizumab plus olaparib versus a next-generation hormonal agent (NHA) for biomarker-unselected, previously treated mCRPC. METHODS: Eligible participants had mCRPC that progressed on or after abiraterone or enzalutamide (but not both) and docetaxel. Participants were randomly assigned (2:1) to pembrolizumab plus olaparib or NHA (abiraterone or enzalutamide). The dual primary end points were radiographic progression-free survival (rPFS) by blinded independent central review per Prostate Cancer Working Group-modified RECIST 1.1 and overall survival (OS). Time to first subsequent therapy (TFST) was a key secondary end point. Safety and objective response rate (ORR) were secondary end points. RESULTS: Between May 30, 2019, and July 16, 2021, 529 participants were randomly assigned to pembrolizumab plus olaparib and 264 to NHA. At final rPFS analysis, median rPFS was 4.4 months (95% CI, 4.2 to 6.0) with pembrolizumab plus olaparib and 4.2 months (95% CI, 4.0 to 6.1) with NHA (hazard ratio [HR], 1.02 [95% CI, 0.82 to 1.25]; P = .55). At final OS analysis, median OS was 15.8 months (95% CI, 14.6 to 17.0) and 14.6 months (95% CI, 12.6 to 17.3), respectively (HR, 0.94 [95% CI, 0.77 to 1.14]; P = .26). At final TFST analysis, median TFST was 7.2 months (95% CI, 6.7 to 8.1) versus 5.7 months (95% CI, 5.0 to 7.1), respectively (HR, 0.86 [95% CI, 0.71 to 1.03]). ORR was higher with pembrolizumab plus olaparib versus NHA (16.8% v 5.9%). Grade ≥3 treatment-related adverse events occurred in 34.6% and 9.0% of participants, respectively. CONCLUSION: Pembrolizumab plus olaparib did not significantly improve rPFS or OS versus NHA in participants with biomarker-unselected, heavily pretreated mCRPC. The study was stopped for futility. No new safety signals occurred.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Antonarakis ES, Park SH, Goh JC, et al. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol. 2023. PMID: 37290035. doi:10.1200/JCO.23.00233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。